Valuation: SIGA Technologies, Inc.

Market Cap 228M 202M 188M 171M 322M 21.62B 327M 2.26B 884M 11.28B 855M 837M 35.96B P/E 2026 *
63.4x
P/E 2027 * 2.94x
Enterprise Value 110M 97.54M 90.4M 82.25M 155M 10.41B 158M 1.09B 426M 5.43B 412M 403M 17.32B EV / Sales 2026 *
1.83x
EV / Sales 2027 * 0.49x
Free-Float
57.27%
Yield 2026 *
18.9%
Yield 2027 * 18.9%
1 week-0.32%
Current month-7.35%
1 month-0.32%
3 months-9.48%
6 months-31.07%
Current year-48.45%
1 week 3.04
Extreme 3.035
3.26
1 month 3.04
Extreme 3.035
3.68
Current year 2.83
Extreme 2.83
7.1
1 year 2.83
Extreme 2.83
8.54
3 years 2.83
Extreme 2.83
12.83
5 years 2.83
Extreme 2.83
26.99
10 years 1.9
Extreme 1.9
26.99
Manager TitleAgeSince
Chief Executive Officer 54 2024-01-26
Director of Finance/CFO 55 2011-02-09
Chief Operating Officer - 2019-12-31
Director TitleAgeSince
Director/Board Member 73 2009-03-10
Director/Board Member 72 2020-06-15
Director/Board Member 42 2020-12-09
Date Insider Type Main position Quantity % Market Cap. Importance
3/25/26 Exercice

General Counsel

17,366 0.0243%
3/13/26 Exercice

General Counsel

121,769 0.1700%
3/13/26 Exercice

Chief Technology Officer

81,787 0.1142%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.32%-62.85%-39.54% 228M
-0.73%+5.56%+54.32%+111.30% 1,120B
-1.31%-4.51%+30.00%+65.34% 616B
-0.66%+1.05%+22.41%+95.20% 504B
-0.05%+5.22%+34.76%+58.86% 367B
-0.60%-0.21%+68.15%+44.53% 360B
-0.17%+3.38%+19.09%+46.34% 288B
-0.46%+2.99%-1.42%+18.10% 258B
-1.18%+2.58%+41.21%+52.65% 234B
-1.28%+2.87%+25.70%+97.28% 194B
Average -0.64%+2.65%+23.14%+55.00% 394.11B
Weighted average by Cap. -0.73%+3.52%+37.47%+76.06%

Financials

2026 *2027 *
Net sales 59.86M 53.21M 49.32M 44.87M 84.68M 5.68B 86.04M 593M 232M 2.96B 225M 220M 9.45B 162M 144M 134M 121M 229M 15.38B 233M 1.6B 629M 8.03B 608M 595M 25.58B
Net income 3.72M 3.31M 3.06M 2.79M 5.26M 353M 5.35M 36.84M 14.44M 184M 13.96M 13.66M 587M 77.88M 69.23M 64.17M 58.38M 110M 7.39B 112M 771M 302M 3.86B 292M 286M 12.3B
Net Debt -118M -105M -97.25M -88.48M -167M -11.2B -170M -1.17B -458M -5.85B -443M -434M -18.64B -148M -131M -122M -111M -209M -14.04B -213M -1.46B -574M -7.33B -555M -543M -23.35B
Projected Income Statement - Annual - SIGA Technologies, Inc.
Logo SIGA Technologies, Inc.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Employees
49
Date Price Change Volume
26-10-19 US$3.150 -0.63% 93,780
26-10-16 US$3.170 -0.63% 909,065
26-10-15 US$3.190 +2.90% 711,095
26-10-14 US$3.100 +0.65% 331,166
26-10-13 US$3.080 -2.53% 293,523
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - SIGA Technologies, Inc.

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - SIGA Technologies, Inc.
  1. Stock Market
  2. Stocks
  3. SIGA Stock